Algenex SL has been recognised as the best European company in the Animal Health Awards 2021 by IHS Markit Agribusiness.
Algenex has more than 20 years’ experience in the veterinary sector and is focused on developing and producing veterinary vaccines using its TopBac® and CrisBio® technology platforms.
We have successfully produced more than 200 molecules in collaboration with public and private partners, including multiple international pharmaceutical companies and achieved proof-of- concept in more than 20 indications across most livestock species.
FatrovaxRHD, first vaccine produced in CrisBio® received marketing authorization in the European Union and United Kingdom in Q3.
Benefits of using CrisBio® in the production of proteins for veterinary vaccines:
-
Linear scalability
-
Reduced production costs
-
Increased productivity, reaching gram per litre yields
Most advanced projects
RHDV
PCV2
BVD
INFLUENZA
H7N9
African Swine Fever
AB rapid detection test
Partnerships
Algenex has a long track record of successful collaborations with public and private partners on a global scale. Customer satisfaction is one of our top priorities
”
For us, CrisBio® technology represents an important opportunity to expand its portfolio of vaccines for veterinary use with a series of highly innovative products
DIAGNOSTICS
Herdscreen® ASFV, developed jointly between Algenex and GlobalDX, is a point-of-care rapid diagnostic test that identifies animals which have been exposed to the African Swine Fever Virus (ASFV) using whole blood, plasma or serum samples. Herdscreen® uses a highly specific antigen produced using CrisBio®.
This antigen is able to capture antibodies developed during infection with ASFV with 100% specificity and higher sensitivity than a commercial ELISA test, as evidenced in field and experimental samples from infected animals gathered by the European Union Reference Laboratory for African Swine Fever (CISA-INIA).
Herdscreen® ASFV been on the market since 2021. The test is being increasingly adopted by food and meat industry to contribute to certifying the ASFV-infection status through the entire supply chain and as a consequence help reducing disease spread.
